Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study

Tauber, M.; Buche, S.; Reygagne, P.; Berthelot, Jean‐Marie; Aubin, F.; Ghislain, Pierre-Dominique; Cohen, Jean-David; Coquerelle, Pascal; Goujon, E.; Jullien, D.; Brixi, Hédia; Jeudy, G.; Guennoc, Xavier; Martin, Antoine; Brenaut, E.; Hoppé, Emmanuel; Bertolotti, A.; Bardin, Thomas; Delaporte, E.; Allez, Matthieu; Bachelez, Hervé; Sénéschal, Julien; Viguier, Manuelle

doi:10.1016/j.jaad.2014.03.005

Cited by 71 publications

(44 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, an open-label clinical trial failed to show clinical response of AA to etanercept, with some participants even experiencing AA worsening during treatment [87]. Furthermore, there are reports on exacerbation of AA with all three anti-TNFs mentioned above [88]. Similar to AD [89, 90], these disappointing results eliminated a possible role for these biologics in AA, and we were not able to find ongoing clinical trials on anti-TNFs for AA.…”

Section: A Few Broad T Cell Antagonists That Are Ineffective For Aamentioning

confidence: 99%

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

Renert‐Yuval

Guttman‐Yassky

2017

Adv Ther

View full text Add to dashboard Cite

Alopecia areata (AA), a prevalent inflammatory cause of hair loss, lacks FDA-approved therapeutics for extensive cases, which are associated with very poor rates of spontaneous hair regrowth and major psychological distress. Current treatments for severe cases include broad immune-suppressants, which are associated with significant adverse effects, precluding long-term use, with rapid hair loss following treatment termination. As a result of the extent of the disease in severe cases, topical contact sensitizers and intralesional treatments are of limited use. The pathogenesis of AA is not yet fully understood, but recent investigations of the immune activation in AA skin reveal Th1/IFN-γ, as well as Th2, PDE4, IL-23, and IL-9 upregulations. Tissue analyses of both animal models and human lesions following broad-acting and cytokine-specific therapeutics (such as JAK inhibitors and ustekinumab, respectively) provide another opportunity for important insights into the pathogenesis of AA. As reviewed in this paper, numerous novel therapeutics are undergoing clinical trials for AA, emphasizing the potential transformation of the clinical practice of AA, which is currently lacking. Dermatologists are already familiar with the revolution in disease management of psoriasis, stemming from better understanding of immune dysregulations, and atopic dermatitis will soon follow a similar path. In light of these recent developments, the therapeutic arena of AA treatments is finally getting more exciting. AA will join the lengthening list of dermatologic diseases with mechanism-targeted drugs, thus changing the face of AA.

show abstract

Section: A Few Broad T Cell Antagonists That Are Ineffective For Aamentioning

confidence: 99%

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

Renert‐Yuval

Guttman‐Yassky

2017

Adv Ther

View full text Add to dashboard Cite

show abstract

“…This study also noted that tumor necrosis factor alpha-antagonist exposure was three times more likely (reporting odds ratio = 3.0) in patients with alopecia than other adverse drug reactions. Another study found the average duration of exposure to tumor necrosis factor alpha-antagonists before the development of alopecia areata to be 22.5 months [13]. This prospective report found 76% of alopecia areata cases to partially or completely resolve over a mean of 5 months with no difference in alopecia areata resolution between those that discontinued and continued tumor necrosis factor alpha-antagonist treatment.…”

Section: Discussionmentioning

confidence: 92%

Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies

Udkoff

Cohen

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Scalp psoriasis with alopecia is a rare cutaneous reaction to tumor necrosis factor alpha antagonists. This reaction often reverses with discontinuation of the offending drug and initiation of topical treatments; however, irreversible hair loss may occur if a scarring alopecia develops. We describe a woman with Crohn’s disease who developed scalp psoriasis and alopecia secondary to infliximab. She had a remarkable recovery after discontinuation of infliximab and treatment with oral minocycline and topical therapy: mineral oil under occlusion, betamethasone lotion, and sequential coal tar, salicylic acid, and ketoconazole shampoos each day. The patient’s alopecia completely resolved within 4 months of initiating this treatment regimen. In summary, early diagnosis of alopecia secondary to tumor necrosis factor alpha antagonist therapy is crucial in preventing diffuse alopecia and scalp psoriasis. In addition to discontinuing the offending agent, initiating aggressive adjuvant treatment with an oral antibiotic, topical therapies, or both, should be considered to reverse tumor necrosis factor alpha antagonist-induced alopecia and/or scalp psoriasis.

show abstract

“…As a result of the study, it was found as ineffective [79]. Several reports have been published indicating the development of AA during a treatment of anti-TNF-α for another disease [80][81][82][83][84][85][86]. Gorcey et al reported a patient with AU, refractory to various treatment modalities, who was successfully treated with adalimumab, while being treated for the flare of atopic dermatitis [87].…”

Section: Tumor Necrosis Factor (Tnf)-α Inhibitorsmentioning

confidence: 95%

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study

Cited by 71 publications

References 5 publications

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies

New Modalities in the Treatment of Refractory Alopecia Areata

Contact Info

Product

Resources

About